Comparison of university of wisconsin, euro-collins, low-potassium dextran, and krebs-henseleit solutions for hypothermic lung preservation.
OBJECTIVE
We sought to test the effectiveness of 4 different solutions for hypothermic rat lung preservation.


METHODS
One hundred ninety-two rats were used. The rats were divided into 4 groups, and University of Wisconsin, Euro-Collins, low-potassium dextran, or Krebs-Henseleit solution was used in each group. They were further divided into 6 subgroups of 8 rats each. The lungs were preserved at 4 degrees C for 0, 4, 6, 8, 12, or 24 hours, respectively, and lung function was studied by using a living rat perfusion model.


RESULTS
Pulmonary arterial flow decreased in each group after 4 to 6 hours of preservation; the low-potassium dextran group decreased the least and the Krebs-Henseleit group decreased the most. Pulmonary vascular resistance increased in each group after 6 hours of preservation; the Krebs-Henseleit group increased the most. Although airway pressure increased, static lung compliance and gas exchange capacity decreased after 8 hours of preservation; the Krebs-Henseleit group exhibited the worst values. Lung tissue wet/dry weight ratio increased gradually during preservation; the University of Wisconsin group exhibited the least increase. An ultrastructural study indicated the least morphologic changes in the low-potassium dextran group at 24 hours.


CONCLUSIONS
At 4 degrees C, all solutions preserved rat lungs for 4 hours with acceptable function. However, 6 hours of preservation resulted in damaged pulmonary function in some lungs, and this damage increased when preservation time was extended. The lungs preserved in low-potassium dextran solution had the best overall function, but the lungs preserved in University of Wisconsin solution had less edema.
Chien
S
S
Jewish Hospital Cardiothoracic Surgical Research Institute, Division of Thoracic and Cardiovascular Surgery, Department of Surgery, University of Louisville, Louisville, KY 40292, USA.
Zhang
F
F
Niu
W
W
Tseng
M T
MT
Gray
L
L
D000241:Adenosine / Q000494:pharmacology; D000403:Airway Resistance / Q000187:drug effects; D000493:Allopurinol / Q000494:pharmacology; D000818:Animals; D015925:Cryopreservation / Q000379:methods*; D003911:Dextrans / Q000494:pharmacology; D005947:Glucose / Q000494:pharmacology; D005978:Glutathione / Q000494:pharmacology; D006982:Hypertonic Solutions / Q000494:pharmacology; D007328:Insulin / Q000494:pharmacology; D008168:Lung / Q000187:drug effects / Q000502:physiology / Q000648:ultrastructure; D008170:Lung Compliance / Q000187:drug effects; D009926:Organ Preservation / Q000379:methods*; D019188:Organ Preservation Solutions / Q000494:pharmacology*; D009929:Organ Size; D011652:Pulmonary Circulation / Q000187:drug effects; D011887:Raffinose / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D020127:Recovery of Function / Q000187:drug effects; D014325:Tromethamine / Q000494:pharmacology; D014655:Vascular Resistance / Q000187:drug effects
D003911:Dextrans; C037096:Euro-Collins' solution; D006982:Hypertonic Solutions; D007328:Insulin; C074097:Krebs-Henseleit solution; D019188:Organ Preservation Solutions; C055206:University of Wisconsin-lactobionate solution; C083290:low potassium dextran glucose solution; D014325:Tromethamine; D000493:Allopurinol; D005978:Glutathione; D005947:Glucose; D000241:Adenosine; D011887:Raffinose